Glenmark Pharmaceuticals Inc has launched Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1g/vial. Glenmark’s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC.

According to IQVIA sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of approximately USD 37.9 million.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said, “The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark’s continued commitment to expanding access to quality, affordable medicines in the US. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients.”